Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
Chul Kim, MD, MPH
Advertisement
Articles by Chul Kim, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
2
SOHO-02 Trial Will Confirm Sevabertinib’s Frontline NSCLC Benefit
3
MELT-MM Regimen Yields Responses in Relapsed/Refractory Multiple Myeloma
4
Cevostamab Combo Shows Durable Responses in R/R Multiple Myeloma
5